| HOME >> BIOLOGY >> TECHNOLOGY |
Stockholders' equity
Convertible preferred stock 88,328 92,241
Common stock 17 17
Treasury stock (628) (1,209)
Accumulated other comprehensive loss (317) (625)
Accumulated deficit (30,439) (13,167)
Total stockholders' equity 56,961 77,257
Total liabilities and stockholders'
equity $159,073 $174,085
MASIMO CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except share information)
(unaudited)
Three Months Ended June 30, Six Months Ended June 30,
2006 2007 2006 2007
Revenue:
Product $37,845 $47,627 $72,524 $93,391
Royalty and
license fee 17,929 16,053 32,556 29,243
Total revenue 55,774 63,680 105,080 122,634
Cost of goods sold 14,956 17,919 31,094 34,820
Gross profit 40,818 45,761 73,986 87,814
Operating expenses:
Research and
development 3,143 5,460 14,937 10,914
Selling, general and
administrative 15,066 21,577 51,181 42,979
Patent litigation
expenses (proceeds) 64 - (262,601) -
Antitrust litigation 49 465 73 475
Total operating
expenses 18,322 27,502 (196,410) 54,368
Operating income
'/>"/>
| SOURCE Masimo Corporation Copyright©2007 PR Newswire. All rights reserved |